Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Acquires Lifecode Data Interpretation Division

NEW YORK (GenomeWeb) – Vela Diagnostics announced today that it has acquired the data interpretation division of Lifecode, marking its first foray into the genomic results interpretation market.                                                                

"This acquisition puts Vela Diagnostics at the forefront in providing genomics interpretation and reporting," Vela CEO Michael Tillmann said in a statement. "The data interpretation products and services from Lifecode will be connected to Vela Diagnostics' next-generation sequencing Sentosa SQ Reporter software. This will allow for information on approved drugs, clinical trials, and publications along with somatic mutation and druggable targets for oncology based on the latest knowledge."

Singapore-based Vela said that the Lifecode division will be integrated into its Vela Genomics subsidiary, with a genomics interpretation and reporting service slated for launch in the third quarter.

Specific terms of the deal were not disclosed. This acquisition comes about three months after Lifecode was acquired by Indian diagnostics firm MedGenome.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.